武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688765 证券简称：禾元生物 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会 会议资料 | 2025 | 年第三次临时股东会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第三次临时股东会会议议程 | 4 | | 2025 | 年第三次临时股东会会议议案 | 6 | | | 议案一： | 6 | 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议资料 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保武汉禾元生物科技股份有限公司（以下简 称"禾元生物"或"公司"）股东会正常秩序和议事效率，根据《中华人民共和 国公司法》《中华人民共和国证券法》等法律法规及《武汉禾元生物科技股份有 限公司章程》和公司《股东会议事规则》的相关规定，制定以下会议须知，请出 席股东会的全体人员遵守执行。 一、会议期间，全体出席人员应以维护股东的合法权益、保证股东会的正常 秩序和议事效率为原则，认真履行法定义务，自觉遵守股东会纪律，不得侵犯其 他股东的 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1 - The core point of the news is that He Yuan Bio experienced a decline in stock price by 3.29% on November 17, with a trading volume of 531 million yuan [1][2] - On the same day, He Yuan Bio had a financing buy-in amount of 54.18 million yuan and a net financing buy-in of 6.57 million yuan, with a total financing and securities balance of 375 million yuan as of November 17 [1][2] - The company reported a significant increase in the number of shareholders, reaching 47,100, which is an increase of 84,075% compared to the previous period [2] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [2] - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51%, while the net profit attributable to the parent company was -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1 - The restructuring protein concept declined by 1.71%, ranking among the top declines in the concept sector, with notable declines in stocks such as Kexing Pharmaceutical, Haoyuan Pharmaceutical, and Zejing Pharmaceutical [1] - Among the stocks in the restructuring protein concept, 8 stocks saw price increases, with *ST Wanfang, ST Weiming, and Lideman leading with increases of 4.96%, 2.21%, and 1.76% respectively [1] - The restructuring protein concept experienced a net outflow of 742 million yuan from main funds today, with 38 stocks seeing net outflows, and 8 stocks with outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock in the restructuring protein concept was Heyuan Biological, with a net outflow of 82.99 million yuan, followed by Sangfor Guojian, Zhifei Biological, and Zhongyuan Xiehe with net outflows of 59.97 million yuan, 57.83 million yuan, and 56.32 million yuan respectively [2][3] - The stocks with the highest net inflow included *ST Wanfang, Furuida, and Yinuote, with net inflows of 10.67 million yuan, 8.92 million yuan, and 7.75 million yuan respectively [4]

Group 1 - The company has not yet established any collaboration with He Yuan Biotechnology Co., Ltd [2] - The company focuses on the blood products sector and is committed to technology-driven product development [2] - The company maintains an open attitude towards new technologies and closely monitors market dynamics and industry advancements to enhance its overall competitive strength [2]

Core Viewpoint - He Yuan Bio's stock price has experienced a decline of 4.23% year-to-date and 8.12% over the last five trading days, with significant trading activity noted in recent sessions [1][2]. Group 1: Stock Performance - On November 14, He Yuan Bio's stock rose by 2.06%, reaching 87.25 CNY per share, with a trading volume of 95.86 million CNY and a turnover rate of 2.69% [1]. - Year-to-date, He Yuan Bio's stock has dropped by 4.23%, and it has fallen by 8.12% in the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, reflecting a year-on-year decrease of 8.51% [2]. - The company's net profit attributable to shareholders was -121 million CNY, a decline of 8.44% year-on-year [2]. Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1].

Market Performance - The Sci-Tech Innovation Board (STAR Market) index fell by 0.58%, closing at 1379.45 points, with a total trading volume of 4.193 billion shares and a turnover of 181.687 billion yuan, resulting in an average turnover rate of 2.19% [1] - Among the tradable stocks on the STAR Market, 188 stocks closed higher, with 3 stocks rising over 10% and 9 stocks rising between 5% and 10%. Conversely, 396 stocks closed lower, with 7 stocks declining over 10% [1] Turnover Rate Analysis - The turnover rate distribution shows that 3 stocks had a turnover rate exceeding 20%, 14 stocks had a turnover rate between 10% and 20%, and 45 stocks had a turnover rate between 5% and 10% [1] - The highest turnover rate was recorded by Magu Technology at 30.12%, closing up by 5.39%, with a transaction amount of 670 million yuan. He Yuan Biological followed with a turnover rate of 27.54%, closing up by 2.90%, with a transaction amount of 990 million yuan [1][3] Stock Performance - In terms of stock performance, among the stocks with a turnover rate exceeding 5%, 27 stocks rose today, with the highest increases seen in Dekoli (up 11.93%), Ruikeda (up 11.00%), and Yingfang Software (up 8.61%). Conversely, the largest declines were in Artis (down 14.33%), Lais Information (down 12.20%), and World (down 11.12%) [2] - The electronic industry had the most stocks with a turnover rate exceeding 5%, totaling 18 stocks, followed by the power equipment and pharmaceutical sectors with 14 and 9 stocks, respectively [2] Capital Flow - Among the high turnover stocks, 30 stocks experienced net inflows of main funds, with the largest inflows in Shijia Photon (188 million yuan), Baijishenzhou (178 million yuan), and Dekoli (151 million yuan). In contrast, Tianhe Energy, Jinpan Technology, and Artis saw the largest net outflows, totaling 445 million yuan, 180 million yuan, and 163 million yuan, respectively [2] - Recent leverage fund movements indicate that 46 stocks received net purchases of leveraged funds, with the largest increases in financing balances for Artis (552 million yuan), Purun Shares (289 million yuan), and Jinpan Technology (267 million yuan). Conversely, the largest decreases were seen in Jiehuate, Foxit Software, and Xinxiangwei, with reductions of 183 million yuan, 177 million yuan, and 166 million yuan, respectively [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced a significant decline in stock price and financial performance, with a notable drop in trading activity and net outflow of funds [1][2]. Group 2 - As of November 12, He Yuan Bio's stock price increased by 2.33% to 88.00 CNY per share, with a trading volume of 1.16 billion CNY and a market capitalization of 31.46 billion CNY [1]. - The company has seen a net outflow of 11.32 million CNY in principal funds, with large orders showing a buy of 20.27 million CNY and a sell of 27.88 million CNY [1]. - Year-to-date, He Yuan Bio's stock price has decreased by 3.40%, and it has dropped 21.43% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 3 - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]. Group 4 - He Yuan Bio belongs to the pharmaceutical and biological industry, specifically in the blood products sector, and is associated with concepts such as innovative drugs, newly listed stocks, biopharmaceuticals, and mid-cap stocks [2]. - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2]. - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also down 8.44% year-on-year [2].

Core Insights - He Yuan Bio experienced a significant decline of 8.02% in stock price on November 11, with a trading volume of 9.52 billion yuan [1] - The company reported a net financing outflow of 16.81 million yuan on the same day, with a total financing and securities balance of 403 million yuan [1] Group 1: Financial Performance - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51% [2] - The net profit attributable to the parent company was -121 million yuan, reflecting a year-on-year decline of 8.44% [2] Group 2: Shareholder and Market Data - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period [2] - The average number of circulating shares per shareholder decreased to 869 shares, down by 99.85% from the previous period [2] Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice embryo cell recombinant protein expression technology [1] - The main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]

Market Overview - The Sci-Tech Innovation Board (STAR Market) index fell by 1.42%, closing at 1387.53 points, with a total trading volume of 4.281 billion shares and a turnover of 193.197 billion yuan, resulting in an average turnover rate of 2.24% [1] - Among the tradable stocks on the STAR Market, 230 stocks closed higher, with 11 stocks rising over 10%, including ShenGong Co., Mag Valley Technology, and Shangwei New Materials, which hit the daily limit [1] Trading Activity - The highest turnover rates were observed in He Yuan Biological, which closed down 8.02% with a turnover rate of 26.26%, and Xi'an Yicai, which closed down 1.48% with a turnover rate of 25.49% [1] - A total of 41 stocks with a turnover rate exceeding 5% saw price increases, while the largest declines were in Pu Ran Co., He Yuan Biological, and Tengjing Technology, which fell by 9.33%, 8.02%, and 7.99% respectively [1][2] Sector Performance - The electronics sector had the highest number of stocks with a turnover rate exceeding 5%, totaling 23 stocks, followed by the power equipment and computer sectors with 18 and 10 stocks respectively [2] - In terms of capital flow, 41 stocks with high turnover rates experienced net inflows from main funds, with the highest net inflows recorded for Baiwei Storage, Atas, and Huicheng Co., amounting to 281 million yuan, 196 million yuan, and 128 million yuan respectively [2] Leverage Fund Movements - A total of 50 stocks with high turnover rates received net purchases from leveraged funds, with significant increases in financing balances for Atas, Jinpan Technology, and Tengjing Technology, which rose by 614 million yuan, 228 million yuan, and 215 million yuan respectively [2] Notable Stocks - Key stocks with high turnover rates included He Yuan Biological, Xi'an Yicai, and Mag Valley Technology, with respective turnover rates of 26.26%, 25.49%, and 25.07% [3][4] - Stocks such as ShenGong Co. and Mag Valley Technology achieved daily limit increases of 20% [3]